Published in J Urol on April 23, 2008
A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides. J Urol (2011) 0.94
Inflammation and pyroptosis mediate muscle expansion in an interleukin-1β (IL-1β)-dependent manner. J Biol Chem (2015) 0.82
Mechanisms of hemorrhagic cystitis. Am J Clin Exp Urol (2014) 0.81
The c-Jun N-terminal kinase (JNK) pathway is activated in human interstitial cystitis (IC) and rat protamine sulfate induced cystitis. Sci Rep (2016) 0.77
Detrusor myocyte autophagy protects the bladder function via inhibiting the inflammation in cyclophosphamide-induced cystitis in rats. PLoS One (2015) 0.76
Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis. Sci Rep (2016) 0.75
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol (2008) 4.90
American Urological Association guideline on the management of priapism. J Urol (2003) 3.77
AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol (2011) 3.00
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc (2003) 2.75
Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res (2006) 2.59
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol (2012) 1.81
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 1.76
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res (2011) 1.62
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn (2012) 1.56
Chapter 1: The management of erectile dysfunction: an AUA update. J Urol (2005) 1.55
Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn (2010) 1.55
Recruitment of bone marrow derived cells to the bladder after bladder outlet obstruction. J Urol (2009) 1.54
The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy. BJU Int (2013) 1.52
Urodynamic studies in adults: AUA/SUFU guideline. J Urol (2012) 1.51
Histologic comparison of pubovaginal sling graft materials: a comparative study. Urology (2008) 1.48
Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol (2003) 1.46
Overactive bladder: evaluation and management in primary care. Cleve Clin J Med (2005) 1.45
A randomized, controlled clinical trial of a novel intravesical pressure attenuation device for the treatment of stress urinary incontinence. J Urol (2013) 1.38
Early results of pubovaginal sling lysis by midline sling incision. Urology (2002) 1.37
Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res (2006) 1.36
Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res (2008) 1.36
Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res (2003) 1.32
AUA guideline on the pharmacologic management of premature ejaculation. J Urol (2004) 1.28
beta1 integrin is necessary for ureteric bud branching morphogenesis and maintenance of collecting duct structural integrity. Development (2009) 1.27
Understanding the role of stromal fibroblasts in cancer progression. Cell Adh Migr (2012) 1.27
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Porcine dermis interposition graft for repair of high grade anterior compartment defects with or without concomitant pelvic organ prolapse procedures. J Urol (2004) 1.21
The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia (2003) 1.20
Identification of extracellular delta-catenin accumulation for prostate cancer detection. Prostate (2009) 1.19
Approach to management of iatrogenic foreign bodies of the lower urinary tract following reconstructive pelvic surgery. J Urol (2012) 1.19
Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res (2011) 1.18
Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn (2008) 1.14
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol (2009) 1.11
Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res (2012) 1.10
Directed differentiation of embryonic stem cells into bladder tissue. Dev Biol (2007) 1.10
Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS One (2010) 1.07
Dermal transforming growth factor-beta responsiveness mediates wound contraction and epithelial closure. Am J Pathol (2009) 1.05
Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun (2006) 1.05
Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. Differentiation (2008) 1.04
Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One (2011) 1.03
Epidemiology of stress urinary incontinence in women. Curr Urol Rep (2011) 1.02
Patterns and predictors of urodynamics use in the United States. J Urol (2012) 1.02
Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium. J Urol (2008) 1.02
Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res (2008) 1.01
Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology (2006) 1.01
Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS One (2011) 0.99
Obturator foramen dissection for excision of symptomatic transobturator mesh. J Urol (2012) 0.98
Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation. Am J Pathol (2007) 0.98
Urethral injections for female stress incontinence. BJU Int (2006) 0.97
The evaluation and treatment of nocturia: a consensus statement. BJU Int (2011) 0.97
Histopathological evaluation of the uterosacral ligament: is this a dependable structure for pelvic reconstruction? BJU Int (2006) 0.97
Removal of transobturator midurethral sling for refractory thigh pain. Urology (2008) 0.96
Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res (2012) 0.96
Genitourinary fistula experience in Sierra Leone: review of 505 cases. J Urol (2009) 0.95
Loss of epithelial oestrogen receptor α inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models. J Pathol (2011) 0.94
Mesenchymal stem cell recruitment and improved bladder function after bladder outlet obstruction: preliminary data. J Urol (2011) 0.93
Sling failures: what's next? Curr Urol Rep (2004) 0.92
Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol (2010) 0.92
A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One (2013) 0.92
The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction. J Urol (2008) 0.91
Diagnosis and management of outlet obstruction in the female. Curr Opin Urol (2008) 0.91
Bladder tissue formation from cultured bladder urothelium. Dev Dyn (2006) 0.91
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia (2012) 0.91
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol (2009) 0.91
Encapsulation of a porcine dermis pubovaginal sling. J Urol (2003) 0.90
Are patient symptoms predictive of the diagnostic and/or therapeutic value of hydrodistention? Neurourol Urodyn (2005) 0.89
Biocompatibility assessment of synthetic sling materials for female stress urinary incontinence. J Urol (2007) 0.87
Pubovaginal sling and pelvic prolapse repair in women with occult stress urinary incontinence: effect on postoperative emptying and voiding symptoms. Urology (2002) 0.87
Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. Curr Urol Rep (2010) 0.87
Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. Neurourol Urodyn (2012) 0.87
Vaginal mesh update. Curr Opin Urol (2012) 0.86
Vesicovaginal fistula following a transobturator midurethral sling procedure. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.86
Bladder stromal loss of transforming growth factor receptor II decreases fibrosis after bladder obstruction. J Urol (2009) 0.86
The use of a multidisciplinary morbidity and mortality conference to incorporate ACGME general competencies. J Surg Educ (2011) 0.86
Gene targeting to the stroma of the prostate and bone. Differentiation (2008) 0.84
Pelvic organ prolapse (POP) surgery: the evidence for the repairs. BJU Int (2011) 0.84
Repeat urethrolysis after failed urethrolysis for iatrogenic obstruction. J Urol (2003) 0.84
Analysis of patient and technical factors associated with midurethral sling mesh exposure and perforation. Int J Urol (2014) 0.83
Management of obstructive voiding dysfunction after incontinence surgery: lessons learned. Urology (2003) 0.83
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol (2006) 0.83